| Somaiah, Neeta |
NCT04595747: Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) |
|
|
| Active, not recruiting | 2 | 48 | US | Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rogaratinib, BAY-1163877, BAY1163877 | National Cancer Institute (NCI) | Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor, Metastatic Sarcoma, Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8, Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8 | 01/25 | 01/25 | | |
DOSa, NCT04668300: Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma |
|
|
| Recruiting | 2 | 75 | US | Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Oleclumab, Anti-CD73 Monoclonal Antibody MEDI9447, MEDI9447 | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma, Metastatic Osteosarcoma, Recurrent Angiosarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Osteosarcoma, Refractory Dedifferentiated Liposarcoma, Refractory Osteosarcoma | 06/26 | 06/26 | | |
NCT02815995: Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes |
|
|
| Completed | 2 | 56 | US | Durvalumab, Tremelimumab | M.D. Anderson Cancer Center, MedImmune LLC | Advanced and/or Metastatic Sarcoma | 06/24 | 06/24 | | |
NCT05017103: Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study |
|
|
| Terminated | 2 | 6 | US | Sintilimab, Anti-PD-1 Monoclonal Antibody IBI308, Anti-PDCD1 Monoclonal Antibody IBI308, IBI 308, IBI308 | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma | 02/24 | 02/24 | | |
NCT05694871: Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma |
|
|
| Active, not recruiting | 2 | 77 | US | Palbociclib, PD-0332991, Cemiplimab, Cemiplimab RWLC, Immunoglobulin G4, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, CT Scan, Biospecimen collection, Questionnaire Administration | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8, Unresectable Dedifferentiated Liposarcoma | 05/27 | 05/27 | | |
NCT06087263: Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. |
|
|
| Recruiting | 2 | 30 | US | Regorafenib, Stivarga® | M.D. Anderson Cancer Center, Bayer | Gastrointestinal Stromal Tumors | 07/32 | 07/34 | | |
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 230 | US, RoW | Phase 1b: APG-115+pembrolizumab, KEYTRUDA® | Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC | Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST) | 12/24 | 03/25 | | |
NCI-2018-00926, NCT03450122: Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma |
|
|
| Completed | 1 | 15 | US | Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Dendritic Cell-targeting Lentiviral Vector ID-LV305, DCvex-NY-ESO-1, ID-LV305 | M.D. Anderson Cancer Center | HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Myxoid Liposarcoma, Recurrent Synovial Sarcoma | 12/22 | 12/22 | | |
|
NCT06474676: T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. |
|
|
| Not yet recruiting | 1 | 40 | US | Cyclophosphamide, T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy, AttIL2-TIL | M.D. Anderson Cancer Center | Metastatic Soft-tissue Sarcoma | 12/30 | 12/32 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
StrateGIST 1, NCT05489237: First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors |
|
|
| Recruiting | 1 | 269 | Europe, US, RoW | IDRX-42 | IDRx, Inc. | Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer | 04/26 | 09/26 | | |
| Zhu, Xiaofan |
TAK-620-2004, NCT05319353 / 2021-004279-15: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT) |
|
|
| Active, not recruiting | 3 | 80 | Europe, Japan, US, RoW | Maribavir, TAK-620 | Takeda, Takeda Development Center Americas, Inc. | Cytomegalovirus (CMV) | 01/27 | 01/27 | | |
| Recruiting | 2/3 | 1800 | RoW | Blinatumomab (Group A), high-dose methotrexate, Venetoclax (nonRand Group), cyclophosphamide, vincristine, dexamethasone, Blinatumomab (Group B) | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL) | 12/29 | 06/31 | | |
NCT05334823: A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents |
|
|
| Recruiting | 2 | 100 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia | 12/24 | 07/25 | | |
NCT06179524: CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL |
|
|
| Recruiting | 2 | 100 | RoW | CAR-T-19 cell injection | Beijing Yongtai Ruike Biotechnology Company Ltd | Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia | 06/25 | 04/27 | | |
NCT05667506: A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) |
|
|
| Recruiting | 1/2 | 47 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | B-cell Acute Lymphoblastic Leukemia | 07/25 | 12/26 | | |
NCT04501614 / 2019-002549-39: A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
|
|
| Terminated | 1/2 | 11 | Europe, US, RoW | Ponatinib, Chemotherapy Agents | Takeda, Takeda Development Center Americas, Inc. | Pediatric Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL), Ph+ Mixed Phenotype Acute Leukemia (MPAL), Philadelphia Chromosome-Like ALL (Ph-like ALL) | 12/23 | 07/24 | | |
NCT05727683: CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1 | 33 | RoW | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, Fludarabine, Cyclophosphamide | Shanghai Ming Ju Biotechnology Co., Ltd. | Acute Lymphocytic Leukemia | 10/23 | 07/25 | | |
NCT05519384: Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 12 | RoW | JK500 cell injection，cyclophosphamide，Fludarabine | Institute of Hematology & Blood Diseases Hospital, Bejing Institute for Stem Cell and Regenerative Medicine, Institute for Stem cell and Regeneration, Chinese Academy of Sciences | Acute Myeloid Leukemia, Childhood, Relapsed Leukemia, Refractory Leukemia | 11/23 | 12/25 | | |
NCT05495035: Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL |
|
|
| Recruiting | 1 | 22 | RoW | Olverembatinib, APG-2575, Dexamethasone | Institute of Hematology & Blood Diseases Hospital | Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia | 08/24 | 12/24 | | |
NCT01995305: Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents |
|
|
| Available | N/A | | RoW | human whole exome, whole genomic, whole exome | Xiaofan Zhu | Fanconi Anemia, Autosomal or Sex Linked Recessive Genetic Disease, Bone Marrow Hematopoiesis Failure, Multiple Congenital Abnormalities, and Susceptibility to Neoplastic Diseases., Hematopoiesis Maintainance. | | | | |
NCT06355739: CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+ |
|
|
| Recruiting | N/A | 60 | RoW | CAR T cell injection | Zhu Xiaofan | B Lymphocytic Leukemia, B Lymphoblastic Lymphoma | 12/26 | 01/27 | | |
| Zhang, Luo |
NCT05038202: Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis |
|
|
| Active, not recruiting | 4 | 450 | RoW | Bencycloquidium Bromide Nasal Spray, BILITING, Mometasone Furoate Aqueous Nasal Spray, NASONEX | Yingu Pharmaceutical Co., Ltd | Allergic Rhinitis | 04/24 | 06/24 | | |
| Not yet recruiting | 4 | 90 | RoW | Oral Glucocorticoids, methylprednisolone, Oral placebo | Beijing Tongren Hospital | Chronic Rhinosinusitis With Nasal Polyps, Glucocorticoids | 12/24 | 11/25 | | |
NCT05598424: CST1 Predictive Model of Oral Glucocorticoid Therapy Sensitivity for Chronic Rhinosinusitis With Polyps |
|
|
| Recruiting | 4 | 150 | RoW | Oral Glucocorticoids, methylprednisolone | Beijing Tongren Hospital | Chronic Rhinosinusitis With Nasal Polyps, Glucocorticoids | 12/24 | 11/25 | | |
NCT05908032: Study of CM310 in Subjects With Allergic Rhinitis |
|
|
| Completed | 3 | 108 | RoW | CM310, Placebo | Keymed Biosciences Co.Ltd | Allergic Rhinitis | 12/23 | 12/23 | | |
NCT06516302: A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps |
|
|
| Not yet recruiting | 3 | 228 | NA | GR1802, Placebo | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Chronic Rhinosinusitis With Nasal Polyps | 01/26 | 10/26 | | |
| Active, not recruiting | 3 | 296 | Europe, Japan, US, RoW | Benralizumab 30 mg, Matched placebo | AstraZeneca | Nasal Polyposis | 08/24 | 10/25 | | |
|
NCT05436275: A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （CROWNS-2） |
|
|
| Completed | 3 | 180 | RoW | CM310, Placebo | Keymed Biosciences Co.Ltd | Chronic Rhinosinusitis With Nasal Polyposis | 06/24 | 06/24 | | |
NCT06639295: A Study to Evaluate 611 in Patients with Chronic Rhinosinusitis with Nasal Polyps |
|
|
| Not yet recruiting | 3 | 240 | RoW | 611, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Sinusitis, Nasal Polyps | 12/25 | 08/26 | | |
NCT05390255: Establishment of Precise Diagnosis and Treatment System for Refractory Chronic Rhinosinusitis |
|
|
| Recruiting | 3 | 87 | RoW | Mometasone furoate nasal spray hormone, Mometasone furoate nasal spray hormone + oral hormone, Mometasone furoate nasal spray hormone + omalizumab | Beijing Tongren Hospital, Peking Union Medical College Hospital, Beijing Hospital | Sinusitis | 12/24 | 12/24 | | |
| Completed | 2 | 93 | RoW | Interleukin-4 receptor responders 1, Interleukin-4 receptor responders 2, Placebo | Beijing Tongren Hospital | Allergic Rhinitis | 09/22 | 12/22 | | |
NCT05131464: The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Completed | 2 | 46 | RoW | CM310 | Keymed Biosciences Co.Ltd | Chronic Rhinosinusitis With Nasal Polyps | 01/24 | 01/24 | | |
NCT06171074: Study of CM310 in Subjects With Seasonal Allergic Rhinitis |
|
|
| Not yet recruiting | 2 | 100 | RoW | CM310 | Keymed Biosciences Co.Ltd | Seasonal Allergic Rhinitis | 03/25 | 03/25 | | |
| Not yet recruiting | 2 | 80 | RoW | Interleukin-4 receptor responders, Placebo | Beijing Tongren Hospital | Seasonal Allergic Rhinitis | 05/25 | 05/25 | | |
NCT05865496: A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Active, not recruiting | 2 | 90 | RoW | 611, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Sinusitis, Nasal Polyps, Polyps | 05/24 | 07/24 | | |
NCT06372678: Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis |
|
|
| Not yet recruiting | 2 | 90 | RoW | CM326, Placebo | Keymed Biosciences Co.Ltd | Chronic Rhinosinusitis With Nasal Polyps | 06/26 | 06/26 | | |
NCT06439381: Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps |
|
|
| Recruiting | 2 | 120 | RoW | 300mg/600mg of TQH2722 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Rhinosinusitis | 10/25 | 11/25 | | |
| Recruiting | 2 | 120 | RoW | Stapokibart Injection, Placebo | Keymed Biosciences Co.Ltd | Allergic Rhinitis | 10/25 | 10/25 | | |
NCT05908721: Study of CM310 in Patients With Allergic Rhinitis |
|
|
| Completed | 2 | 100 | RoW | CM310 | Keymed Biosciences Co.Ltd | Allergic Rhinitis | 12/23 | 12/23 | | |
NCT06089278: A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. |
|
|
| Recruiting | 2 | 160 | RoW | 300mg of TQH2722 injection, 600mg of TQH2722 injection, TQH2722 injection matching placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Sinusitis | 05/25 | 05/25 | | |
NCT05324137: A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Completed | 1/2 | 88 | RoW | CM326, Placebo | Keymed Biosciences Co.Ltd | Chronic Rhinosinusitis With Nasal Polyps | 03/24 | 03/24 | | |
NCT04052945: Efficacy, Safety and Underlying Mechanisms of Sphenopalatine Ganglion Acupuncture for Seasonal Allergic Rhinitis |
|
|
| Recruiting | N/A | 70 | RoW | SPA acupuncture, sham acupuncture | Beijing Tongren Hospital | Seasonal Allergic Rhinitis | 10/20 | 12/22 | | |
NCT04234451: Efficacy, Safety and Underlying Mechanisms of Sphenopalatine Ganglion Acupuncture for Perennial Allergic Rhinitis |
|
|
| Not yet recruiting | N/A | 40 | RoW | SPA acupuncture, sham acupuncture | Beijing Tongren Hospital | Perennial Allergic Rhinitis | 02/22 | 09/22 | | |
NCT06010316: A Prospective Single-center Cohort Study of Surgical Treatment of Chronic Rhinosinusitis |
|
|
| Recruiting | N/A | 200 | RoW | | Beijing Tongren Hospital | Chronic Rhinosinusitis (Diagnosis), Cohort Study, Evidence-based Medicine | 01/25 | 12/25 | | |
NCT05363423: Lateral Pedicled Nasoseptal Flaps for Endoscopic Draf III Procedure in Patients With Frontal Sinus Inverted Papilloma |
|
|
| Recruiting | N/A | 22 | RoW | Draf III procedure with lateral pedicled nasoseptal flaps applied, Draf III procedure without any flap applied | Beijing Tongren Hospital | Draf III Procedure, Naso-septal Flap, Inverted Papilloma | 05/22 | 06/22 | | |
NCT05428410: Study on Biomarkers to Predict the Efficacy of IL-4R Monoclonal Antibody for Chronic Rhino-sinusitis With Polyps |
|
|
| Not yet recruiting | N/A | 56 | RoW | IL-4R, Placebo | Beijing Tongren Hospital | Chronic Rhino-sinusitis, IL-4R, Monoclonal Antibody, Biomarker | 06/23 | 06/23 | | |
| Eugster, Erica |
NCT05493709: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects with Central Precocious Puberty |
|
|
| Recruiting | 3 | 93 | US, RoW | Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide | Foresee Pharmaceuticals Co., Ltd., QPS Holdings LLC, Changchun GeneScience Pharmaceutical Co., Ltd. | Puberty; Precocious, Central | 11/25 | 06/26 | | |
| Hu, Wei |
TIGER, NCT04255602: A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients |
|
|
| Recruiting | 4 | 2120 | RoW | Ticagrelor 60mg, Ticagrelor 90mg | Shanghai Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Fudan University | Acute Coronary Syndrome, Coronary Stent Implantation | 12/24 | 12/24 | | |
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. |
|
|
| Recruiting | 3 | 1600 | RoW | rhNRG-1, Neucardin™, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Heart Failure | 02/26 | 02/26 | | |
ASSET-IT, NCT06134622: Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis |
|
|
| Recruiting | 3 | 832 | RoW | Intravenous thrombolysis plus tirofiban, Intravenous thrombolysis plus placebo | The First Affiliated Hospital of University of Science and Technology of China | Acute Ischemic Stroke | 12/26 | 06/27 | | |
NCT05701956: Intravenous Tenecteplase Plus EVT Versus EVT Alone on 4.5 to 24 Hours After Basilar Artery Occlusion |
|
|
| Recruiting | 3 | 332 | RoW | Tenecteplase, TNK, TNK-tPA, TNKase, rhTNK-tPA, Endovascular thrombectomy, thrombectomy | The First Affiliated Hospital of University of Science and Technology of China | Basilar Artery Occlusion, Acute Cerebrovascular Accident, Stroke Due to Basilar Artery Occlusion | 12/25 | 03/26 | | |
NCT05827042: Endovascular Thrombectomy Alone Versus Intravenous Thrombolysis Plus Thrombectomy on Acute Basilar Artery Occlusion |
|
|
| Recruiting | 3 | 338 | RoW | Intravenous thrombolysis, Alteplase or Tenecteplase, Endovascular thrombectomy | The First Affiliated Hospital of University of Science and Technology of China | Basilar Artery Occlusion, Acute Cerebrovascular Accident, Stroke Due to Basilar Artery Occlusion | 12/25 | 03/26 | | |
NCT05684172: Intra-arterial TNK Following Endovascular Thrombectomy in Patients With Large Vessel Occlusion of Posterior Circulation |
|
|
| Completed | 2/3 | 208 | RoW | Tenecteplase, endovascular thrombectomy alone | The First Affiliated Hospital of University of Science and Technology of China | Acute Ischemic Stroke, Intracranial Artery Occlusion, Endovascular Thrombectomy | 08/23 | 11/23 | | |
NCT04973735: A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects |
|
|
| Active, not recruiting | 1 | 42 | RoW | LY-CovMab | Luye Pharma Group Ltd., Shandong Boan Biotechnology Co Ltd | Covid19 | 05/21 | 07/21 | | |
NCT05166837: The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects |
|
|
| Completed | 1 | 52 | RoW | STSA-1002 injection, Placebo | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Healthy | 01/23 | 01/23 | | |
NCT05659927: Single Dose Clinical Trial of MG-ZG122 in Chinese Healthy Adult Subjects |
|
|
| Active, not recruiting | 1 | 34 | RoW | MG-ZG122 Humanized Monoclonal Antibody Injection, MG-ZG122, Placebo | Shanghai Mabgeek Biotech.Co.Ltd | Asthma | 01/24 | 03/24 | | |
NCT05865574: A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection |
|
|
| Not yet recruiting | 1 | 38 | RoW | BAT1706 Injection, BAT1706 | Bio-Thera Solutions | Healthy Men | 09/23 | 01/24 | | |
NCT05968508: A Randomized, Double-blind, Single-dose, Two-arm Parallel Study to Compare the Pharmacokinetics and Safety of BAT1806 Prefilled Subcutaneous Injection With RoActemra® in Healthy Chinese Male Subjects |
|
|
| Active, not recruiting | 1 | 300 | RoW | BAT1806 prefilled subcutaneous injection/RoActemra® (from EU) | Bio-Thera Solutions | Healthy Men | 12/24 | 04/25 | | |
NCT06182384: A Clinical Study to Compare the Safety and Pharmacokinetics of SHR-1314 Injection in Healthy Subjects at Different Specifications Devices |
|
|
| Completed | 1 | 46 | RoW | SHR-1314 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Moderate-to-Severe Plaque Psoriasis | 05/24 | 05/24 | | |
NCT06196580: PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval |
|
|
| Completed | 1 | 24 | RoW | repaglinide; midazolam; SHR4640, repaglinide; midazolam; SHR4640; SHR4640 placebo, repaglinide; midazolam; SHR4640 placebo | Jiangsu HengRui Medicine Co., Ltd. | Gout and Hyperuricemia | 02/24 | 02/24 | | |
| Recruiting | 1 | 84 | RoW | HS-10501 tablet, Placebo | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Healthy Subjects | 01/25 | 06/25 | | |
| Completed | 1 | 65 | RoW | HDM1005 injection or placebo | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Obesity and Overweight | 08/24 | 09/24 | | |
NCT06346925: Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects. |
|
|
| Not yet recruiting | 1 | 18 | RoW | Herombopag Olamine Tablets | Jiangsu HengRui Medicine Co., Ltd. | Adult Patients With Chronic Primary ITP, Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy | 07/24 | 07/24 | | |
NCT06171048: Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 236 | RoW | CM310 | Keymed Biosciences Co.Ltd | Healthy | 04/25 | 04/25 | | |
NCT06375031: Comparison of HR011408 and NovoRapid® in Subjects With Diabetics |
|
|
| Recruiting | 1 | 30 | RoW | HR011408 injection; HR011408 injection Placebo, NovoRapid®; HR011408 injection Placebo, HR011408 injection Placebo; HR011408 injection | Jiangsu HengRui Medicine Co., Ltd. | Diabetes | 07/24 | 07/24 | | |
NCT06422039: Bioavailability and Food Effects of HRS-7535 Tablets With Different Formulating Processes in Healthy Subjects |
|
|
| Not yet recruiting | 1 | 18 | RoW | HRS-7535（D）Tablets, HRS-7535（C）Tablets | Shandong Suncadia Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 06/24 | 06/24 | | |
NCT06435676: A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects |
|
|
| Recruiting | 1 | 92 | RoW | HRS9531, Placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Overweight or Obesity; Type 2 Diabetes | 09/24 | 09/24 | | |
| Recruiting | 1 | 50 | RoW | HDM1005 injection or placebo, HDM1005 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Overweight and Obesity | 01/25 | 01/25 | | |
| Not yet recruiting | 1 | 60 | RoW | DA-302168S, Placebo of DA-302168S | Chendu DIAO Pharmaceutical Group CO., LTD. | Overweight and Obesity | 06/25 | 09/25 | | |
HDG1901-103, NCT06634927: Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. |
|
|
| Recruiting | 1 | 68 | RoW | Ozempic®, HDG1901 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 11/24 | 02/25 | | |
NCT06654960: Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects |
|
|
| Completed | 1 | 20 | RoW | HRS9531 injection, Metformin Hydrochloride tablets | Fujian Shengdi Pharmaceutical Co., Ltd. | Type 2 Diabetes | 12/24 | 12/24 | | |
NCT06723691: Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects |
|
|
| Active, not recruiting | 1 | 57 | RoW | Acetaminophen, Metformin, Warfarin, Atorvastatin, Digoxin, HRS9531 | Fujian Shengdi Pharmaceutical Co., Ltd. | Type 2 Diabetes | 05/25 | 05/25 | | |
NCT05295329: Effect of Compound Danshen Dripping Pills on Diabetic Patients With Coronary Microcirculation Disturbance |
|
|
| Not yet recruiting | N/A | 120 | RoW | Compound Danshen Dropping Pills, Placebo | Ruijin Hospital | Diabetes | 09/22 | 12/22 | | |
NCT05119647: A Single-Arm Objective Performance Criteria Trial for Intracranial Thrombus Aspiration Catheter |
|
|
| Completed | N/A | 124 | RoW | Thrombus Aspiration Catheter(Ton-bridgeMT) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Acute Ischemic Stroke | 08/22 | 11/22 | | |
| Active, not recruiting | N/A | 60 | RoW | MG-K10 humanized monoclonal antibody injection (prefilled syringe), MG-K10 (prefilled syringe), MG-K10 humanized monoclonal antibody injection（Penicillin bottle）, MG-K10 （Penicillin bottle） | Shanghai Mabgeek Biotech.Co.Ltd, The Second Hospital of Anhui Medical University | Pharmacokinetics | 01/24 | 08/24 | | |
NCT06146790: Evaluation of Endovascular Treatment in Acute Intracranial Distal Medium Vessel Occlusion Stroke |
|
|
| Recruiting | N/A | 564 | RoW | endovascular treatment, Standard medical management | The First Affiliated Hospital of University of Science and Technology of China | Acute Ischemic Stroke, Endovascular Thrombectomy | 12/25 | 03/26 | | |
SOLUTION-2, NCT06374667: The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction |
|
|
| Recruiting | N/A | 134 | RoW | Y-3 ICO injection, Y-3 intravenous injection, Conventional treatment | yilong Wang | Stroke, Acute Ischemic, Blood-Brain Barrier | 03/26 | 03/27 | | |
NCT06559436: Extending the Time Window for Intravenous Tenecteplase in Patients With Distal Medium Vessel Occlusions Stroke |
|
|
| Recruiting | N/A | 560 | RoW | Intravenous thrombolysis, Standard medical management | The First Affiliated Hospital of University of Science and Technology of China | Acute Ischemic Stroke | 09/26 | 12/26 | | |
NCT06559475: A Multicenter, Randomized Controlled Clinical Investigation to Evaluate the Safety and Effectiveness of the Super-Bore 8/7F Aspiration Catheters in the Treatment of Acute Intracranial Large Vessel Occlusion |
|
|
| Recruiting | N/A | 360 | RoW | Super-Bore Thrombosis Aspiration Catheter treatment group, Conventional thrombectomy device treatment group | The First Affiliated Hospital of University of Science and Technology of China | Acute Ischemic Stroke, Endovascular Thrombectomy | 12/25 | 04/26 | | |
NCT06794801: Evaluating the Safety and Efficacy of Drug-Coated Autoperfusion Balloons Versus Conventional Drug-Coated Balloons Guided by IVUS-OCT Multimodal Imaging for Treating Acute Myocardial Infarction: OPERA-AMI Study |
|
|
| Not yet recruiting | N/A | 134 | RoW | Drug Coated Autoperfusion Balloon Dilatation Catheter（DCAB）, Conventional Drug coated balloon (DCB), Bingo® PTCA Drug Delivery System | LanZhou University | ST Segment Elevation Myocardial Infarction (STEMI) | 12/26 | 12/30 | | |
BEST-BAO, NCT05631847: Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke |
|
|
| Recruiting | N/A | 336 | RoW | Endovascular treatment, Intravenous thrombolysis (Alteplase) | Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital | Acute Ischemic Stroke, Basilar Artery Occlusion, Thrombosis, Alteplase, Endovascular Treatment | 01/27 | 05/27 | | |
NCT05450757: Shanghai ST-segment Elevation Myocardial Infarction Cohort |
|
|
| Recruiting | N/A | 2000 | RoW | | Ruijin Hospital | ST Elevation Myocardial Infarction | 09/23 | 09/24 | | |
| Zhang, Ye |
NCT05840341: Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer |
|
|
| Recruiting | 3 | 306 | RoW | QingyiHuaji optimized formula, standard chemotherapy | Fudan University | Pancreatic Neoplasms | 12/25 | 12/25 | | |
NCT03915132: Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 47 | RoW | Nimotuzumab, Taixinsheng, VMAT | Chinese Academy of Medical Sciences | Nasopharyngeal Carcinoma | 05/20 | 05/22 | | |
NCT05202275: The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs |
|
|
| Recruiting | 2 | 43 | RoW | Olanzapine, Palonosetron, Aprepitant | Chinese Academy of Medical Sciences | Nausea, Vomiting, Head and Neck Squamous Cell Carcinoma, Radiotherapy Side Effect | 12/22 | 09/23 | | |
| Enrolling by invitation | N/A | 51 | RoW | Hypofractionated Radiation Therapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE, Hypofractionation | 12/26 | 12/26 | | |
NCT05375721: Prevention of PONV With Traditional Chinese Medicine |
|
|
| Recruiting | N/A | 300 | RoW | ST36 acupoint injection | The Second Hospital of Anhui Medical University, The First Affiliated Hospital with Nanjing Medical University, Huashan Hospital, Henan Provincial People's Hospital, The Affiliated Hospital of Xuzhou Medical University, First Affiliated Hospital of Jinan University, Beijing Chao Yang Hospital | Postoperative Nausea and Vomiting | 02/24 | 05/24 | | |
NCT06469034: Mixed Reality and Head-mounted Display for Central Venous Catheterization |
|
|
| Recruiting | N/A | 124 | RoW | conventional ultrasound, Mixed reality and head-mounted display ultrasound | The Second Hospital of Anhui Medical University | Central Venous Catheterization | 06/25 | 06/25 | | |
NCT05060068: Effect of Intravenous S-ketamine on Opioid Consumption |
|
|
| Completed | N/A | 345 | RoW | S-ketamine (low dose), LKET, Placebo, CON, S-ketamine (high dose), HKET | The Second Hospital of Anhui Medical University | Breast Cancer Surgery | 07/24 | 07/24 | | |
NCT05607225: Deep Learning-based Classification and Prediction of Radiation Dermatitis in Head and Neck Patients |
|
|
| Recruiting | N/A | 300 | RoW | | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Radiation Dermatitis, Head and Neck Cancer | 06/25 | 06/25 | | |
| Li, Jun |
NCT04270279: Efficacy and Safety of Xueshuanxinmaining Tablet for the Treatment of Stable Angina Pectoris |
|
|
| Not yet recruiting | 4 | 120 | NA | Xueshuanxinmaining tablet, XSXMN, Xueshuanxinmaining placebo, XSXMN placebo, Nitroglycerin tablets | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Coronary Heart Disease, Stable Angina | 08/21 | 10/21 | | |
NCT04270071: Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris |
|
|
| Not yet recruiting | 4 | 80 | NA | Yangxin Shengmai, YXSM, Yangxin Shengmai placebo, YXSM placebo, nitroglycerin tablets | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Coronary Heart Disease, Stable Angina | 10/21 | 12/21 | | |
| Active, not recruiting | 4 | 640 | RoW | Tenofovir Amibufenamide（TMF）, HS-10234 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Hepatitis B, Chronic | 06/24 | 09/29 | | |
NCT05305872: Gandouling in the Treatment of Wilson's Disease |
|
|
| Recruiting | 4 | 240 | RoW | Gandouling, zinc gluconate | Jun Li | Wilson's Disease | 03/23 | 12/24 | | |
NCT04661709: Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris |
|
|
| Not yet recruiting | 4 | 502 | NA | Wen Xin granule, WXG, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Aspirin Enteric-coated Tablets, WXG placebo, Trimetazidine Dihydrochloride Tablets, glyceryl trinitrate | Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Special Project of National Traditional Chinese Medicine Clinical Research Base of State Administration of Traditional Chinese Medicine, National Natural Science Foundation of China | Coronary Heart Disease, Unstable Angina, Chinese Herbal Medicine | 03/23 | 06/23 | | |
NCT04532606: Impact of Remimazolam on Prognosis After Bladder Cancer Surgery |
|
|
| Recruiting | 4 | 1128 | RoW | Remimazolam, Remimazolam anesthesia, Propofol, Propofol anesthesia | Peking University First Hospital, Beijing Tsinghua Chang Gung Hospital, Navy General Hospital, Beijing, Guizhou Provincial People's Hospital, Jiangsu Provincial People's Hospital, Shanghai 10th People's Hospital | Benzodiazepines, Bladder Cancer, Delirium, Surgery, Cancer Recurrence | 10/24 | 10/25 | | |
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. |
|
|
| Completed | 3 | 248 | RoW | Hydronidone capsules, F351, The placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Liver Fibrosis | 10/24 | 10/24 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
